Researchers interested in understanding the broader context of GLP-1 receptor agonist research can explore how tirzepatide compares to other compounds in this class through our semaglutide versus tirzepatide comparison , the mazdutide comparison , and our overview of peptides for weight loss more broadly
Type 2 Diabetes: Rosenstock et al., 2023 (Lancet) Rosenstock, Fras, Jastreboff, and colleagues reported a phase 2, randomized, double-blind, placebo- and active-controlled, parallel-group trial in The Lancet in 2023 [5]
People who stopped the drug after using it for diabetes often need to go back on it or switch to another diabetes medication
Having professional guidance available during those moments helps patients stay focused and motivated
Bertelli PR, Mocelin R, Marcon M, Sachett A, Gomez R, Rosa AR, et al
Inquire if the person has experienced nausea, early satiety, bloating, vomiting, reflux, or constipation